Policy & Practice

View the latest content related to this topic

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

The novel dissolvable therapy had a 93.2% probability of being cost-effective at a modest willingness-to-pay level.

L.A. McKeown

April 24, 2025

Slides

See all

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Bryan Kindya

February 28, 2025

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Laura Young

February 28, 2025

Presentation CTO 2025

Lessons from My First Year(s) in Practice

Presenter: Pratik Sandesara

February 28, 2025

Presentation Controversies and Advances 2025

The role of double-blind sham-controlled trials in interventional cardiology

Presenter: Rasha Al-Lamee

January 31, 2025

Presentation Controversies and Advances 2025

The Good, the Bad and the Ugly of Clinical Trial Design

Presenter: Stuart Pocock

January 31, 2025

News

See all

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

By Michael O'Riordan

April 25, 2025

News Daily News

Funding for Women’s Health Initiative Imperiled, But Appears Secure for Now

By Yael L. Maxwell

April 25, 2025

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

By L.A. McKeown

April 24, 2025

News Daily News

HRS, ACC Lay Out Principles for Same-Day Discharge After Catheter Ablation

By Todd Neale

April 24, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

By Michael O'Riordan

April 22, 2025

ACC 2025

March 29

March 31, 2025

CTO 2025

February 28

March 01, 2025

THT 2025

February 11

February 13, 2025

Videos on This Topic

See all

Advertisement

Policy & Practice

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

Slides

Lessons from My First Year(s) in Practice

Lessons from My First Year(s) in Practice

Lessons from My First Year(s) in Practice

The role of double-blind sham-controlled trials in interventional cardiology

The Good, the Bad and the Ugly of Clinical Trial Design

News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Funding for Women’s Health Initiative Imperiled, But Appears Secure for Now

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

HRS, ACC Lay Out Principles for Same-Day Discharge After Catheter Ablation

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

More on This Topic

Conference Coverage

ACC 2025

CTO 2025

THT 2025

Videos on This Topic

Advertisement

Policy & Practice

Slides

News

More on This Topic

Conference Coverage

Videos on This Topic

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content